- Oops!Something went wrong.Please try again later.
Alopecia areata is an autoimmune disorder that results in patchy or complete hair loss.
The data showed that relative to the previous Phase 2 study results of CTP-543, hair regrowth was maintained or improved in the majority of patients through one year of continuous dosing with 12 mg twice-daily of CTP-543.
Approximately 57% of participants receiving 12 mg of CTP-543 twice-daily following 52 weeks of dosing achieved a clinically meaningful disease severity score of 20 or less.
Dosing in the long-term extension study is ongoing, and patients completing the ongoing Phase 3 THRIVE-AA trials are eligible to enroll in the study.
These data will be presented virtually during the virtual JAK Inhibitors Drug Development Summit.
The company plans to file a marketing application in early 2023.
Price Action: CNCE shares are down 2.65% at $4.11 during the market session on the last check Thursday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.